Ixekizumab safe to use in Pediatric Patients with Moderate to Severe Plaque Psoriasis: JAMA

The key findings of this study were as follow:

1. A total of 171 patients were randomly assigned to receive either ixekizumab (n = 115) or a placebo (n = 56).

2. 139 (83.7%) of the 166 participants who started the maintenance stage completed week 108 of the experiment.

3. Patients achieved PASI 75, PASI 90, PASI 100, sPGA 0 or 1, and sPGA 0.

4. Primary and gated secondary end goals were maintained through week 108, with patients reaching PASI 75, PASI 90, PASI 100, sPGA 0 or 1, and sPGA 0.

5. Fifty-five patients (78.5%) reported an Itch Numeric Rating Scale improvement of four points or greater.

6. At week 108, elimination of nail psoriasis was reported in 68.1% (n = 28), palmoplantar psoriasis was reported in 90.0% (n = 10), scalp psoriasis was recorded in 76.2% (n = 83), and genital psoriasis was reported in 87.5% (n = 24) of patients who took ixekizumab.

7. During weeks 48 to 108 of the trial, there were no new safety findings, including no new occurrences of inflammatory bowel disease or candida infection.

In conclusion, the safety of ixekizumab was similar to previous reported findings in this cohort and the treatment's established safety profile.

Reference:

Paller AS, Seyger MMB, Magariños GA, et al. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. JAMA Dermatol. Published online April 13, 2022. doi:10.1001/jamadermatol.2022.0655